Enzyvant gains double fast-track for rare disease drug
pharmaphorum media | April 18, 2017
The investigational tissue-based therapy is for the treatment of complete DiGeorge Syndrome (cDGS), which represents a tiny subset of patients with the rare condition, DiGeorge Syndrome, caused by a single gene defect.